The proposed shift targets a little-known route for ingredients to enter the U.S. food supply without a formal FDA review. It could reshape how much safety information companies must disclose before using new substances in food.
Robert F. Kennedy Jr. is targeting a decades-old loophole affecting chemicals in the U.S. food supply: companies can self-certify that certain food ingredients are safe without notifying the U.S. Food and Drug Administration. Kennedy has directed the FDA to explore rulemaking that could eliminate that pathway, known as self-affirmed GRAS, and increase oversight and transparency.
The proposal does not immediately ban a specific food chemical or rewrite the rules overnight. Its practical significance is upstream: it could determine whether manufacturers must publicly notify the FDA and provide supporting safety information before certain new ingredients reach grocery shelves.
The rule at the center
GRAS stands for “generally recognized as safe.” Under federal food law, a substance that qualifies as GRAS for its intended use may be exempt from the usual requirement for a food additive review.
The FDA operates a voluntary GRAS Notification Program. Companies can submit notices describing an ingredient, how it will be used and the basis for their safety conclusion. The agency then evaluates the notice and issues a response letter.
But the part drawing Kennedy’s attention is the self-affirmed route. A manufacturer can conclude on its own that a substance is GRAS, provided the conclusion meets the applicable standard, without submitting a GRAS notice to the FDA first.
That distinction matters because a voluntary notice creates a public agency record. A self-affirmation need not trigger the same advance notification or public-facing FDA review.
Kennedy seeks a different gate
The Department of Health and Human Services said Kennedy directed the acting FDA commissioner to explore potential rulemaking to revise the GRAS final rule and related guidance to eliminate the self-affirmed GRAS pathway.
In its announcement, HHS argued that ingredient makers and sponsors have used the pathway to introduce ingredients and chemicals without notification to either the FDA or the public. Kennedy framed the effort as a transparency measure as well as a food-safety measure.
If self-affirmation were eliminated, HHS said companies seeking to introduce new food ingredients would be required to notify the FDA publicly of their intended use and submit underlying safety data before the ingredients enter the food supply.
That is a meaningful change in process, not an assertion that every ingredient currently covered by GRAS is unsafe. The administration’s stated objective is more consistent visibility into the evidence and decisions behind new uses.
What FDA oversight looks like now
The FDA says it strongly encourages manufacturers to file GRAS notices even though a company can self-affirm a GRAS conclusion without doing so. The agency maintains a public inventory of notices it has received, the supporting material provided and its response letters.
According to HHS, the FDA has completed and published more than 1,000 GRAS notices and evaluates an average of 75 notices a year. Those figures show that the notification program is already a substantial channel for ingredient review and public disclosure.
Still, voluntary participation leaves an information gap. Consumers, researchers and even food buyers can inspect the FDA’s notice inventory, but they cannot use it as a complete list of all substances companies have independently determined to be GRAS.
Acting FDA Commissioner Sara Brenner said the agency is committed to safeguarding the food supply through appropriate review of ingredients and substances that come into contact with food. Any final policy would have to work within FDA authority and available resources.
Transparency is the immediate stakes
The debate can sound technical, but it reaches a familiar consumer concern: Who has seen the safety evidence for an ingredient before it appears in food?
Supporters of ending self-affirmation are likely to see a clearer premarket notification requirement as a basic accountability measure. It could make it easier for outside scientists, journalists and consumers to know what ingredients are being introduced and what data support their use.
Industry and food manufacturers may focus on the practical costs and timing of a more formal process. Requiring notification and FDA engagement for every covered use could add administrative work and potentially slow product development, depending on how a final rule is written and staffed.
Those are not mutually exclusive concerns. A rule can promise greater disclosure while raising legitimate questions about review capacity, scientific standards, confidential business information and the timeline for agency decisions.
What the announcement does not settle
Kennedy directed the FDA to explore rulemaking. That is an early policy step, not a final regulation. The announcement does not establish a deadline for a proposed rule, specify the exact legal language the FDA would pursue or say how pending and existing GRAS determinations would be treated.
It also remains unclear whether rulemaking alone would fully close the pathway. HHS said it plans to work with Congress on potential legislation, describing legislation and future rulemaking as complementary steps.
A formal FDA rulemaking process would ordinarily involve a proposed rule, public comments and a final rule. That gives food companies, consumer advocates, scientists and other stakeholders an opportunity to press competing arguments about safety evidence, implementation and costs.
For now, the clearest takeaway is procedural: the administration wants to move more ingredient safety decisions into a system where the FDA is notified before products reach the market and the public can see more of the supporting record.
A policy shift worth watching
Food labels may not change immediately, and the HHS announcement does not identify particular products for removal. The near-term story is about how future ingredients and uses could be evaluated, documented and disclosed.
For consumers, greater transparency would not automatically answer every question about a food ingredient. It could, however, make the questions easier to ask with a public FDA filing and safety rationale available for review.
The GRAS debate also illustrates the difference between an ingredient being permitted under a legal framework and the public having a simple way to inspect the evidence behind that decision. Kennedy’s proposed direction to the FDA is aimed squarely at narrowing that gap.
Leave a Reply